Literature DB >> 2451370

Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema.

T Ruzicka1, J Ring.   

Abstract

The releasability of arachidonic acid-derived inflammatory mediators (eicosanoids) from peripheral blood leukocytes has been tested in patients with atopic eczema and healthy, non-atopic controls. Spontaneous and stimulated release of prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and leukotriene C4 (LTC4) has been measured after challenge of cells with various concentrations of anti-IgE, Ca-ionophore A23187 and C5a. The maximal stimulation of cells with Ca-ionophore resulted in the generation of high amounts of all eicosanoids, which was essentially equal in both atopic and control groups. On the other hand, enhanced spontaneous and stimulated eicosanoid release was noted after immunological challenge using C5a and anti-IgE in the atopic eczema group. Thus, our data support the hypothesis of enhanced releasability of inflammatory mediators in atopic eczema.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2451370

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  8 in total

1.  Conversion of leukotriene A4 by neutrophils and platelets from patients with atopic dermatitis.

Authors:  R A Hilger; K Neuber; W König
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

2.  Comparison of histamine release and prostaglandin E2 production of human basophils in atopic and normal individuals.

Authors:  D von der Helm; J Ring; W Dorsch
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis.

Authors:  K Neuber; R A Hilger; W König
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

4.  Enhanced prostaglandin E2 production by monocytes in atopic dermatitis (AD) is not accompanied by enhanced production of IL-6, IL-10 or IL-12.

Authors:  A Snijders; T C Van der Pouw Kraan; M Engel; J Wormmeester; P Widjaja; I M Zonneveld; J D Bos; M L Kapsenberg
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

Review 5.  The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field.

Authors:  Eustachio Nettis; Maddalena D'Erasmo; Elisabetta Di Leo; Gianfranco Calogiuri; Vincenzo Montinaro; Antonio Ferrannini; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2010-09-22       Impact factor: 4.711

6.  Enhanced procoagulant activity of mononuclear leukocytes in patients with atopic dermatitis and psoriasis.

Authors:  R E Schopf; H Weber; B Morsches
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

Review 7.  Treatment of atopic eczema with evening primrose oil: rationale and clinical results.

Authors:  M J Kerscher; H C Korting
Journal:  Clin Investig       Date:  1992-02

8.  In vitro antioxidative and anti-inflammatory effects of the compound K-rich fraction BIOGF1K, prepared from Panax ginseng.

Authors:  Muhammad Jahangir Hossen; Yong Deog Hong; Kwang-Soo Baek; Sulgi Yoo; Yo Han Hong; Ji Hye Kim; Jeong-Oog Lee; Donghyun Kim; Junseong Park; Jae Youl Cho
Journal:  J Ginseng Res       Date:  2016-01-06       Impact factor: 6.060

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.